TEVJF — TEVA PHARMACEUTICAL INDUSTRIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 818686 ·
Israel
Last close
$30.34
Market Cap
$35.33B
52W High
$37.00
52W Low
$28.36
ADV30
20
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,981,000,000 | 1,972,000,000 | 759,000,000 | 369,000,000 | 40,040,000,000 | 3,741,000,000 | 31,808,000,000 |
| Dec 2025 | 4,711,000,000 | 2,656,000,000 | 1,269,000,000 | 480,000,000 | 40,748,000,000 | 3,556,000,000 | 32,834,000,000 |
| Sep 2025 | 4,480,000,000 | 2,304,000,000 | 1,075,000,000 | 433,000,000 | 39,856,000,000 | 2,203,000,000 | 32,602,000,000 |
| Jun 2025 | 4,176,000,000 | 2,102,000,000 | 899,000,000 | 282,000,000 | 40,131,000,000 | 2,161,000,000 | 33,297,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,714,000,000
Investing CF
$765,000,000
Financing CF
$-394,000,000
CapEx
$-542,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,394,000,000
Inventory
$3,176,000,000
Receivables
$3,393,000,000
ST Investments
—
EBIT TTM
$2,271,000,000
Pretax Income TTM
$1,366,000,000
Interest Exp TTM
$905,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,348,999,168
EBITDA
$5,002,999,808
Free Cash Flow
$2,611,375,104
Enterprise Value
$48,516,714,496
Total Cash
$3,740,999,936
Total Debt
$16,924,999,680
Shares Out
1,164,426,972
Trailing EPS
$1.34
Book Value
$7.07
ROE
21.6%
ROA
6.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,257,000,000 | 3,952,000,000 | 1,410,000,000 | 40,748,000,000 | 32,834,000,000 | — | 1,649,000,000 |
| Dec 2024 | 16,544,000,000 | 3,364,000,000 | -1,639,000,000 | 39,326,000,000 | 33,606,000,000 | — | 1,247,000,000 |
| Dec 2023 | 15,845,000,000 | 3,194,000,000 | -559,000,000 | 43,479,000,000 | 35,353,000,000 | — | 1,368,000,000 |
| Dec 2022 | 14,925,000,000 | 2,690,000,000 | -2,446,000,000 | 44,011,000,000 | 35,413,000,000 | — | 1,590,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZTS | Zoetis Inc. | $34.46B | $82.20 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $39.75B | $297.69 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.11B | $34.45 | — |
| BEIGF | BeOne Medicines Ltd. | $27.76B | $22.50 | — |
| TKPHF | TAKEDA PHARMACEUTICAL CO LTD | $48.14B | $30.47 | — |
News headlines (Yahoo Finance, 1h cache)
Is Amneal a Buy Before Rytary Generic Erosion?
2026-06-09 15:56 · Yahoo
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Gro
2026-06-09 04:30 · Yahoo
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
2026-06-08 12:00 · Yahoo
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?
2026-06-08 10:06 · Yahoo
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
2026-06-08 08:00 · Yahoo
Veeva Falcon AI Rollout Tests Investor Patience After Share Price Slide
2026-06-06 01:05 · Yahoo
Sector Update: Healthcare Stocks Gain Friday Afternoon
2026-06-05 17:50 · Yahoo
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
2026-06-05 17:31 · Yahoo
Teva Says AUSTEDO Improves Quality of Life in Huntington's Disease Study
2026-06-05 16:42 · Yahoo
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
2026-06-05 15:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.